Redmile Group, LLC Entrada Therapeutics, Inc. Transaction History

Redmile Group, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$11.85 - $16.45 $8.56 Million - $11.9 Million	-722,764 Reduced 56.3%	560,971 $7.99 Million
Q4 2023 Feb 14, 2024	SELL	$11.36 - $16.99 $316,228 - $472,950	-27,837 Reduced 2.12%	1,283,735 $19.4 Million
Q2 2023 Aug 14, 2023	SELL	$11.02 - $18.01 $5.73 Million - $9.37 Million	-520,036 Reduced 28.39%	1,311,572 $19.9 Million
Q1 2023 May 15, 2023	SELL	$9.58 - $16.2 $215,550 - $364,500	-22,500 Reduced 1.21%	1,831,608 $26.6 Million
Q4 2022 Feb 14, 2023	SELL	$13.52 - $22.89 $1.36 Million - $2.3 Million	-100,311 Reduced 5.13%	1,854,108 $25.1 Million
Q1 2022 May 16, 2022	SELL	$7.99 - $16.93 $7 - $16	-1 Reduced -0.0%	1,954,419 $18.4 Million
Q4 2021 Feb 14, 2022	BUY	$13.7 - $35.0 $26.8 Million - $68.4 Million	1,954,420 New	1,954,420 $33.5 Million

101

28.1M

34.5K

16.4K

Ticker TRDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,368,500
Market Cap $551M
Description
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Redmile Group, LLC with notifications on news.